DexCom (DXCM): Cutting PT On Temporary Market Weakness - Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Feltl & Co Downgrades Tandem Diabetes Care (TNDM) to Buy
November 2, 2016 10:52 AM EDTFeltl & Co downgraded Tandem Diabetes Care (NASDAQ: TNDM) from Strong Buy to Buy.
For an analyst ratings summary and ratings history on Tandem Diabetes Care click here. For more ratings news on Tandem Diabetes Care click here.
Shares of Tandem Diabetes Care closed at $5.35 yesterday.
... MoreLeerink Partners Cuts Price Target on DexCom (DXCM) Following 3Q
November 2, 2016 8:29 AM EDTLeerink Partners maintained an Outperform rating on DexCom (NASDAQ: DXCM), and cut the price target to $100.00 (from $115.00), following the company's 3Q earnings report. DXCM reported revenue of $148.6M, ahead of the Streets $146.6M. Higher OpEx drove EPS below expectations.
Analyst Danielle Antalffy commented, "DXCM shares could underperform today despite a 3Q16 sales beat given: (1) The company... More
